Correction to: Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction

Correction to: Protein Cell 10.1007/s13238-019-0623-2

In Fig. 7C, we used the ERCC6^mut-iPSCs (CS-iPSCs) as NANOG-positive control pluripotent cells in the upper panels. However, these cells were inadvertently labeled as ERCC6^GC-iPSCs. In the revised version of Fig. 7C, we have updated the high-quality images along with the corrected mark. In addition, we have also made corresponding changes in the figure legend.

Figure 7.

Safety analysis of gene-corrected CS-MSCs obtained under a cGMP-compliant condition. (A) FACS analysis indicated the expression of the cell surface markers CD73, CD90 and CD105 in CS-MSCs and GC-MSCs. (B) RT-qPCR analysis of the expression of pluripotency markers OCT4, NANOG, and SOX2 in CS-MSCs and GC-MSCs. GC-iPSCs and CS-fibroblasts were used as positive and negative controls, respectively. Data are presented as the mean ± SEM, n = 3. (C) Immunostaining of the pluripotency marker NANOG in CS-MSCs and GC-MSCs. CS-iPSCs were used as a positive control, Scale bar, 50 μm. (D) Whole-genome sequencing of single-nucleotide variants (SNVs) in CS-fibroblasts, CS-iPSCs, GC-iPSCs, CS-MSCs and GC-MSCs. Sites with a heterozygosity percentage ranging between 0% and 30% were considered as SNV sites, and sites with a heterozygosity of >30% were considered as single-nucleotide polymorphisms (SNPs). (E) Whole-genome sequencing of copy number variations (CNVs) in CS-fibroblasts, CS-iPSCs, GC-iPSCs, CS-MSCs and GC-MSCs. Each point represents normalized coverage depth of each 500-kb genomic region of each chromosome. (F) Sterility and pathogen testing of the conditioned medium of GC-MSCs. ^a Endotoxin was identified as negative when the concentration was < 0.25 EU/mL. ^b CMV was identified as negative when the ratio of the OD450 value of sample to the cutoff value (S/Co) was < 1.0. ^c HAV was identified as negative when the ratio of the cut-off value to the OD450 nm value of the sample (Co/S) was < 0.9. ^d HCV was identified as negative when the ratio of the OD450 value of the sample to the cut-off value (S/Co) was < 0.9. ^e HIV-1 was identified as negative when the concentration = 0 pg/mL. (G) Evaluation of the potential tumorigenesis risk of GC-MSCs in vivo. A subcutaneous injection of GC-MSCs was performed in immune-deficient mice. Human ESC (line H9) and U2-OS osteosarcoma cell lines were also implanted independently as positive controls. Representative images in the lower panel showing the teratoma and tumor formed from positive cells two months after transplantation, Scale bar, 0.5 cm. HE staining of a teratoma and tumor were shown in the upper panel. Scale bar, 100 μm. The in vivo tumor-formation incidence of each cell type was calculated. n = 4 for each positive cell group, n = 5 for the GC-MSC group